IRAK3 and neoplasm: A total of 80% of IRAK3-KO mice receiving a PD-1 blocking antibody showed small tumors (< 200 mm3) at day 40 after tumor implantation, compared with 16% of anti-PD-1–treated WT mice (Figure 7A).